$FITX Letter to Shareholders

BEVERLY HILLS, CA and LAKESHORE, ON–(Marketwired – Mar 12, 2015) – Creative Edge Nutrition, Inc. (OTC PINK:FITX), a nutritional supplement company focusing on active lifestyles, announces a letter to its shareholders.

Dear Shareholders,

Over the past several weeks there has been much speculation regarding the status of CEN Biotech’s application filed with Health Canada in September 2013 for licensure as a medicinal marijuana producer under Canada’s MMPR program. As you may know, back on February 13, 2015, Health Canada issued the Company a “Letter of Intent to Deny” CEN Biotech’s application, which letter was not received by CEN Biotech until February 18, 2015.

On March 11, 2015, CEO Bill Chaaban was personally served with a rejection notice from Health Canada, rejecting the application of CEN Biotech, and thereby denying the Company a license to produce medicinal marijuana under Canada’s MMPR program. It is the Company’s understanding that no internal investigation was conducted in denying the License, but rather resulted from mischaracterizations in the media intended to destroy CEN Biotech’s reputation in the Court of public opinion. Due to CEN Biotech’s never ending affinity for its loyal shareholders, it will not sit idly by and allow mischaracterizations and the dissemination of falsities to destroy the Company, but will continue to fight and utilize all legal means to continue to fight for licensure.

Specifically, due to the factual misrepresentations and fraud disseminated by certain news agencies and unscrupulous bashers seeking to soil the Company’s reputation in the court of public opinion for the purpose of monetary and political gain, the Company has turned to the federal court of Canada for determination of whether CEN has complied with all of the requirements for license issuance. The determination regarding licensure must be dependent on the true facts and evidence, which until now, have seemingly gone unnoticed. CEN Biotech firmly believes that when the Court reviews the facts surrounding the application, and not fraudulent representations, unsupported statements and mischaracterizations, that it will quickly agree with our position. Facts cannot be ignored, and the facts surrounding the CEN Biotech application support issuance of a license.

An example of such untruths is the rumor that CEN Biotech failed to satisfy the zoning requirements of the Town of Lakeshore, where the initial facility is located. However, contrary to this misrepresentation, the town council of Lakeshore specifically determined that CEN Biotech’s facility was properly zoned as agricultural as well as indicating that CEN Biotech had requested to grow 600,000 kg of dried marijuana. Documentation of these facts is contained on pages 31-32 of the official Minutes of the Lakeshore November 12, 2013 Town Council meeting, which may be found in the link below.

The Company has the highest confidence in the federal court to finally have an unbiased and scrupulous review of the true facts involved with its application, which facts the Company believes will prove to the Court that CEN Biotech has in fact complied with all requirements under the MMPR for issuance of a license to grow.

CEN Biotech remains committed to protecting its loyal shareholders’ equity investments, (as has been the case since Health Canada issued the Company a “Ready to build” letter) by exhausting all legal avenues available for procurement of a license to grow. We ask that you trust in our quest for transparency, which has been our goal since the inception of the Company. Because of your support, and the respect in our vision, we are here today and that is the sole reason we will be here tomorrow.

Hopefully, as we believe, the Company will be successful in the mandamus suit presently pending in federal court, and we can move forward toward providing those patients in need (most notably the children who depend on such medicine to curb epileptic and other seizures) with quality medicinal marijuana.

About CEN Biotech
CEN Biotech, Inc. was established in 2013 as a partially owned subsidiary of Creative Edge Nutrition (OTC PINK: FITX) (PINKSHEETS: FITX) for the sole purpose of supplying the Canadian public with pharmaceutical-grade medical cannabis under the newly established Marihuana for Medical Purposes Regulations (MMPR). CEN Biotech Inc. has submitted a comprehensive application to become a licensed producer (LP) of dried marihuana for medicinal purposes and has received a ready-to-build approval from Health Canada. https://www.cenbiotechinc.com info@cenbiotechinc.com

About Creative Edge Nutrition, Inc.
Creative Edge Nutrition, Inc., is a holding company and a Nutritional Supplement Company focused on developing innovative, high quality supplements and energy drinks. The company offers a broad spectrum of capsules, tablets, and powders, as well as science based products in the principal categories of weight management, nutrition challenges, energy and fitness. The Company manufactures under strict GMP guidelines at GMP Certified and/or FDA registered facilities.www.CenergyNutrition.com

Company Disclaimer

As a “penny stock” Company, within the meaning of federal and state securities law, Creative Edge Nutrition, Inc. may not avail itself of the Safe Harbor provisions as identified in the Private Securities Litigation Reform Act of 1995. However, Creative Edge Nutrition, Inc. provides the following disclaimer and warning to protect our shareholders, prospective investors and the public at large by alerting them to the risks and uncertainties involved with any investment, and the need to perform their own due diligence and assessment.

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

CEN Biotech, Inc.
20 North Rear Road
Lakeshore, Ontario